Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy

Koshy, Sandeep T.; Cheung, Alexander S.; Gu, Luo; Graveline, Amanda; Mooney, David J.

doi:10.1002/adbi.201600013

Cited by 207 publications

(205 citation statements)

References 46 publications

Supporting

Mentioning

196

Contrasting

Order By: Relevance

“…For example, for a nanovaccine made of a gold nanoparticle core and a shell of CpG oligonucleotides (CpG ODN), a Toll-like receptor 9 (TLR9) agonist was used for delivering CpG to inhibit tumour growth 166 . Liposome was also studied to improve lymph-node-targeted delivery of cyclic di-GMP (cdGMP), a potential robust immunostimulatory adjuvant 167,168 . In addition to synthetic nanocarriers, naturally derived nanovaccines have been explored because of their good biocompatibility.…”

Section: Challenges and New Opportunitiesmentioning

confidence: 99%

Rethinking cancer nanotheranostics

et al. 2017

View full text Add to dashboard Cite

Advances in nanoparticle synthesis and engineering have produced nanoscale agents affording both therapeutic and diagnostic functions that are often referred to by the portmanteau ‘nanotheranostics’. The field is associated with many applications in the clinic, especially in cancer management. These include patient stratification, drug-release monitoring, imaging-guided focal therapy and post-treatment response monitoring. Recent advances in nanotheranostics have expanded this notion and enabled the characterization of individual tumours, the prediction of nanoparticle–tumour interactions, and the creation of tailor-designed nanomedicines for individualized treatment. Some of these applications require breaking the dogma that a nanotheranostic must combine both therapeutic and diagnostic agents within a single, physical entity; instead, it can be a general approach in which diagnosis and therapy are interwoven to solve clinical issues and improve treatment outcomes. In this Review, we describe the evolution and state of the art of cancer nanotheranostics, with an emphasis on clinical impact and translation.

show abstract

Section: Challenges and New Opportunitiesmentioning

confidence: 99%

Rethinking cancer nanotheranostics

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Afterward, the authors applied their fusogenic liposomes to treat mice with solid lymphomas . Mooney and co‐workers also developed a cationic liposome to deliver STING agonists, which resulted in the suppression of metastatic melanoma tumors in the lung . In 2016, Moon and co‐workers developed a hybrid liposome that combined cationic lipids and HA for delivering the intranasal vaccine, F1‐V, against Yersinia pestis , the causative agent of plague …”

Section: Nanoscale Materials For Immunotherapymentioning

confidence: 99%

Materials for Immunotherapy

et al. 2019

View full text Add to dashboard Cite

Breakthroughs in materials engineering have accelerated the progress of immunotherapy in preclinical studies. The interplay of chemistry and materials has resulted in improved loading, targeting, and release of immunomodulatory agents. An overview of the materials that are used to enable or improve the success of immunotherapies in preclinical studies is presented, from immunosuppressive to proinflammatory strategies, with particular emphasis on technologies poised for clinical translation. The materials are organized based on their characteristic length scale, whereby the enabling feature of each technology is organized by the structure of that material. For example, the mechanisms by which i) nanoscale materials can improve targeting and infiltration of immunomodulatory payloads into tissues and cells, ii) microscale materials can facilitate cell‐mediated transport and serve as artificial antigen‐presenting cells, and iii) macroscale materials can form the basis of artificial microenvironments to promote cell infiltration and reprogramming are discussed. As a step toward establishing a set of design rules for future immunotherapies, materials that intrinsically activate or suppress the immune system are reviewed. Finally, a brief outlook on the trajectory of these systems and how they may be improved to address unsolved challenges in cancer, infectious diseases, and autoimmunity is presented.

show abstract

“…The Harashima group also established YSK05 liposomes to deliver CDG and the loaded YSK05 liposomes induced NK cell activation and MHC‐I nonrestricted antitumor activity through the STING pathway . Similarly, Mooney et al designed a series of cationic liposomes with different amounts of PEG to load 2′,3′‐cGAMP (Figure ) . PEG (0%) lipo‐cGAMP induced more cGAMP cellular uptake and higher gene expression of the CD86 marker and IFN‐β in vitro compared with other formulations.…”

Section: Sting Agonistsmentioning

confidence: 99%

“…Cationic liposomes designed by the Mooney group for cGAMP delivery . A, Schematic of the cGAMP‐loading liposome structure.…”

Section: Sting Agonistsmentioning

confidence: 99%

Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy

Zhao

et al. 2019

Medicinal Research Reviews

114

View full text Add to dashboard Cite

Since being discovered in 2008, the STING (stimulator of interferon genes) pathway has gradually been recognized as a central and promising target for immunotherapy. The STING pathway can be stimulated by cyclic dinucleotides (CDNs), leading to the type I interferons (IFN) production for immunotherapy for cancer or other diseases. However, the negative charges, hydrophilicity, and instability of CDNs have hindered their further applications. In addition, chronic activation of the STING pathway has been found to be involved in autoimmune diseases as IFN overproduction.Thus, research and development of STING agonists and inhibitors has been a hot field for the treatment of several diseases. The past several years, especially 2018, has seen increasingly rapid advances in this field. Here, this review summarizes the synthesis and modification of CDNs, the identification of nonnucleotide agonists, the recent progress in delivery systems and the medical applications, such as personalized vaccine adjuvants, in detail. In addition, in this review, we summarize the STING inhibitors' advances from two aspects, covalent, and noncovalent inhibitors. K E Y W O R D S agonist, cyclic dinucleotides, immunotherapy, inhibitor, STING

show abstract

Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy

Cited by 207 publications

References 46 publications

Rethinking cancer nanotheranostics

Rethinking cancer nanotheranostics

Materials for Immunotherapy

Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy

Contact Info

Product

Resources

About